Calls
1
u/yellowbai
Reddit r/ValueInvesting
Win Rate
0.0%
return
-2.7%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Aug 19
$46.62
-2.7%
GLP-1 drugs like Ozempic/Wegovy are showing strong real-world adoption and increasing trust among GPs. Once insurers see these drugs reduce long-term healthcare costs, prescription volumes could scale massively — even if generics eventually appear. The market is mispricing Novo Nordisk’s long-term growth runway in weight-loss and metabolic disease. Slow insurance adoption, policy/pricing pressure, competition from Lilly and others, or clinical/safety setbacks could invalidate the thesis. No other actionable trade ideas in this post.
GLP-1 drugs like Ozempic/Wegovy are showing strong real-world adoption and increasing trust among GPs. Once insurers see these drugs reduce long-term healthcare costs, prescription volumes could scale massively — even if generics eventually appear. The market is mispricing Novo Nordisk’s long-term growth runway in weight-loss and metabolic disease. Slow insurance adoption, policy/pricing pressure, competition from Lilly and others, or clinical/safety setbacks could invalidate the thesis. No other actionable trade ideas in this post.
GLP-1 / Obesity
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/yellowbai has 1 trade ideas tracked on Buzzberg across 1 tickers since August 2026. Most covered: NVO.
